Meeting
2021 ASCO Annual Meeting
A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer.
Authors
Yuan Yuan
City of Hope National Medical Center, Duarte, CA
Yuan Yuan , Susan Elaine Yost , Paul Henry Frankel , Christopher Ruel , Mireya Murga , Aileen Tang , Norma Martinez , James Ross Waisman , Daphne B. Stewart , Niki Himat Patel , Joanne E. Mortimer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03853707
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1078)
DOI
10.1200/JCO.2021.39.15_suppl.1078
Abstract #
1078
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).
First Author: David B. Page
Poster
2022 ASCO Annual Meeting
Association of 27-gene IO score with outcome in a phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in metastatic triple-negative breast cancer (mTNBC).
First Author: David B. Page
Poster
2018 ASCO Annual Meeting
Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC).
First Author: David B. Page
Poster
2015 ASCO Annual Meeting
Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial.
First Author: Mario Campone